Testing PARP Inhibitors Using a Murine Xenograft Model

Peter Makhov; Sei Naito; Vladimir M Kolenko

doi:10.1007/978-1-4939-6993-7_20

Testing PARP Inhibitors Using a Murine Xenograft Model

Methods Mol Biol. 2017:1608:313-320. doi: 10.1007/978-1-4939-6993-7_20.

Authors

Peter Makhov¹, Sei Naito², Vladimir M Kolenko³

Affiliations

¹ Cancer Biology Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
² Department of Urology, Yamagata University Faculty of Medicine, Iida-nishi 2-2-2, Yamagata, 990-9585, Japan.
³ Cancer Biology Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA. Vladimir.Kolenko@fccc.edu.

PMID: 28695518
DOI: 10.1007/978-1-4939-6993-7_20

Abstract

Animal models are indispensable research tools for various drug discovery and development applications. In cancer research, the growth of tumors in vivo is necessary in order to closely modulate a potential response in humans. Ectopic (subcutaneous) xenografting of human cancer cells into immunodeficient mice has long been the standard model for preclinical evaluation of novel antitumor therapeutic agents. Here, we describe the establishment and use of subcutaneous xenograft mouse model to evaluate the antitumor activity of PARP-1 inhibitors.

Keywords: Cancer; Model; Mouse; PARP-1; Subcutaneous; Xenograft.

MeSH terms

Animals
Antineoplastic Agents / therapeutic use*
Disease Models, Animal
Humans
Mice
Mice, SCID
Neoplasms / drug therapy*
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
Xenograft Model Antitumor Assays / methods*

Substances

Antineoplastic Agents
Poly(ADP-ribose) Polymerase Inhibitors